PET/CT imaging in cancer: Current applications and future directions
- 19 June 2014
- Vol. 120 (22), 3433-3445
- https://doi.org/10.1002/cncr.28860
Abstract
Positron emission tomography (PET) is a radiotracer imaging method that yields quantitative images of regional in vivo biology and biochemistry. PET, now used in conjunction with computed tomography (CT) in PET/CT devices, has had its greatest impact to date on cancer and is now an important part of oncologic clinical practice and translational cancer research. In this review of current applications and future directions for PET/CT in cancer, the authors first highlight the basic principles of PET followed by a discussion of the biochemistry and current clinical applications of the most commonly used PET imaging agent, 18F‐fluorodeoxyglucose (FDG). Then, emerging methods for PET imaging of other biologic processes relevant to cancer are reviewed, including cellular proliferation, tumor hypoxia, apoptosis, amino acid and cell membrane metabolism, and imaging of tumor receptors and other tumor‐specific gene products. The focus of the review is on methods in current clinical practice as well as those that have been translated to patients and are currently in clinical trials. Cancer 2014;120:3433–3445. © 2014 American Cancer Society.Keywords
This publication has 117 references indexed in Scilit:
- Early identification of antigen-specific immune responses in vivo by [ 18 F]-labeled 3′-fluoro-3′-deoxy-thymidine ([ 18 F]FLT) PET imagingProceedings of the National Academy of Sciences of the United States of America, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast CancerClinical Pharmacology & Therapeutics, 2010
- Imaging Cellular Proliferation During Chemo-Radiotherapy: A Pilot Study of Serial 18F-FLT Positron Emission Tomography/Computed Tomography Imaging for Non–Small-Cell Lung CancerInternational Journal of Radiation Oncology*Biology*Physics, 2009
- Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib FailureClinical Cancer Research, 2009
- Prospective Trial Incorporating Pre-/Mid-Treatment [18F]-Misonidazole Positron Emission Tomography for Head-and-Neck Cancer Patients Undergoing Concurrent ChemoradiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 2009
- 18F-FDG PET and 18F-FDG PET/CT for Assessing Response to Therapy in Esophageal CancerJournal of Nuclear Medicine, 2009
- Early Detection of Erlotinib Treatment Response in NSCLC by 3′-Deoxy-3′-[18F]-Fluoro-L-Thymidine ([18F]FLT) Positron Emission Tomography (PET)PLOS ONE, 2008
- Early Response Assessment in Gastrointestinal Stromal Tumors With FDG PET Scan 24 Hours After a Single Dose of ImatinibClinical Nuclear Medicine, 2008
- Prognostic Significance of 99mTc Hynic-rh-Annexin V Scintigraphy During Platinum-Based Chemotherapy in Advanced Lung CancerJournal of Clinical Oncology, 2007